Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update

+3.33% Pre

AADI BIOSCIENCE INC

AADI

3.10

3.04

+3.33%

-1.78% Pre

LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com.

About Aadi Bioscience

Aadi is a precision oncology company focused on the commercialization of FYARRO^® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:

IR@aadibio.com

(PRNewsfoto/Aadi Bioscience)

View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-third-quarter-2024-results-and-corporate-update-302291958.html

SOURCE Aadi Bioscience

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.